highlighted TLR4 as the key LPS receptor activating immune responses, with significantly higher activation rates observed in sepsis patients compared to healthy individuals, offering prospects for targeted therapy based on TLR-4 activation status (56). This evidence concerns the gene TLR4 and Sepsis.